Relmada Therapeutics (NASDAQ:RLMD) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Relmada Therapeutics and Dicerna Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Relmada Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
| Dicerna Pharmaceuticals | 0 | 0 | 7 | 0 | 3.00 |
Relmada Therapeutics currently has a consensus target price of $63.3333, suggesting a potential upside of 85.02%. Dicerna Pharmaceuticals has a consensus target price of $37.4286, suggesting a potential upside of 36.60%. Given Relmada Therapeutics' higher probable upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than Dicerna Pharmaceuticals.
Profitability
This table compares Relmada Therapeutics and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Relmada Therapeutics | N/A | -32.03% | -31.41% |
| Dicerna Pharmaceuticals | -88.81% | -71.72% | -16.60% |
Earnings and Valuation
This table compares Relmada Therapeutics and Dicerna Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Relmada Therapeutics | N/A | N/A | N/A | ($2.16) | -15.85 |
| Dicerna Pharmaceuticals | $23.90 million | 87.50 | $-120,460,000.00 | ($1.76) | -15.57 |
Relmada Therapeutics has higher earnings, but lower revenue than Dicerna Pharmaceuticals. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Relmada Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.
Insider and Institutional Ownership
64.3% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. 9.3% of Relmada Therapeutics shares are held by company insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Dicerna Pharmaceuticals beats Relmada Therapeutics on 8 of the 12 factors compared between the two stocks.
